Global Mantle Cell Lymphoma Therapeutics Market 2019-2023

マントル細胞リンパ腫治療法の世界市場:併用療法、単独療法

◆タイトル:Global Mantle Cell Lymphoma Therapeutics Market 2019-2023
◆商品コード:IRTNTR31758
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2019年7月31日
◆ページ数:131
◆資料形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:アジア太平洋、ヨーロッパ、北米、その他
◆産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥280,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥336,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥448,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

Technavio社の本調査レポートでは、マントル細胞リンパ腫治療法の世界市場について調べ、マントル細胞リンパ腫治療法の市場状況、市場規模、市場予測、市場環境、顧客状況、市場動向、関連企業情報などをまとめました。また、マントル細胞リンパ腫治療法の市場規模をセグメンテーション別(製品別(併用療法、単独療法)、)と地域別(アジア太平洋、ヨーロッパ、北米、その他)に分けて算出しました。Technavio社はマントル細胞リンパ腫治療法の世界市場規模が2019-2023期間中に年平均7%成長すると予測しています。
・サマリー
・レポートの範囲
・マントル細胞リンパ腫治療法の市場状況
・マントル細胞リンパ腫治療法の市場規模
・マントル細胞リンパ腫治療法の市場予測
・マントル細胞リンパ腫治療法の世界環境:ファイブフォース分析
・市場セグメンテーション:製品別(併用療法、単独療法)
・マントル細胞リンパ腫治療法の顧客状況
・主要地域別市場規模:アジア太平洋、ヨーロッパ、北米、その他
・意思決定フレームワーク
・市場動向・成長要因・課題
・関連企業状況・企業分析
 ...

Global Mantle Cell Lymphoma Therapeutics Market: About this market

Mantle cell lymphoma therapeutics are available in combination therapy and monotherapy. Technavio’s mantle cell lymphoma therapeutics market analysis considers sales from the combination therapy and monotherapy segments. Our analysis also considers the sales of mantle cell lymphoma therapeutics in Asia, Europe, North America, and ROW. In 2018, the combination therapy segment held the highest market share, which is expected to remain prevalent over the forecast period. Factors such as the reduced drug resistance and rising development and commercialization of combination therapies will significantly help the market segment in maintaining its leading position. Also, our global mantle cell lymphoma therapeutics report has observed market growth factors such as recent approvals, introduction of targeted therapies, and growth of geriatric population. However, adverse effects of available therapeutics, limited access to treatment, and presence of stringent regulations may hamper the growth of the mantle cell lymphoma therapeutics industry over the forecast period.

Global Mantle Cell Lymphoma Therapeutics Market: Overview

Recent approvals

The significant unmet need for the treatment of mantle cell lymphoma has given the market vendors scope to develop reliable therapeutics. The rising formulation of therapeutics has prompted many approvals in the last few years, increasing the sales of vendors. As a result, recent approvals will lead to the expansion of the mantle cell lymphoma therapeutics market at a CAGR of over 7% during the forecast period.

Advent of novel therapies

Vendors are formulating advanced therapeutics to cater to the market demand. For instance, kinase inhibitors and gene therapies exhibit high efficacy, increasing their demand. Therefore, this trend will have a positive impact on the overall market growth.

For the detailed list of factors that will drive the global mantle cell lymphoma therapeutics market during the forecast period 2019-2023, click here.

Competitive Landscape

With the presence of several major players, the global mantle cell lymphoma therapeutics market is concentrated. Technavio’s robust vendor analysis is designed to help clients in improving their market positions, and in line with this, this report provides a detailed analysis of several leading mantle cell lymphoma therapeutics manufacturers, which include Allergan Plc, AstraZeneca Plc, Celgene Corp., Johnson & Johnson Services Inc., and Takeda Pharmaceutical Co. Ltd.

Also, the mantle cell lymphoma therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

【資料の目次】

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

2.1 Preface

2.2 Preface

2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

Market ecosystem

Market characteristics

Market segmentation analysis

PART 04: MARKET SIZING

Market definition

Market sizing 2018

Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

Bargaining power of buyers

Bargaining power of suppliers

Threat of new entrants

Threat of substitutes

Threat of rivalry

Market condition

PART 06: MARKET SEGMENTATION BY PRODUCT

Market segmentation by product

Comparison by product

Combination therapy – Market size and forecast 2018-2023

Monotherapy – Market size and forecast 2018-2023

Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

Geographic segmentation

Geographic comparison

North America – Market size and forecast 2018-2023

Europe – Market size and forecast 2018-2023

Asia – Market size and forecast 2018-2023

ROW – Market size and forecast 2018-2023

Key leading countries

Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

Market drivers

Market challenges

PART 11: MARKET TRENDS

Advent of novel therapies

Research grants and funding

Special drug designations

PART 12: VENDOR LANDSCAPE

Overview

Landscape disruption

Competitive scenario

PART 13: VENDOR ANALYSIS

Vendors covered

Vendor classification

Market positioning of vendors

Allergan Plc

AstraZeneca Plc

Celgene Corp.

Johnson & Johnson Services Inc.

Takeda Pharmaceutical Co. Ltd.

PART 14: APPENDIX

Research methodology

List of abbreviations

Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

Exhibit 01: Product overview

Exhibit 02: Global pharmaceuticals market

Exhibit 03: Segments of global pharmaceuticals market

Exhibit 04: Market characteristics

Exhibit 05: Market segments

Exhibit 06: Market definition – Inclusions and exclusions checklist

Exhibit 07: Market size 2018

Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)

Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)

Exhibit 10: Five forces analysis 2018

Exhibit 11: Five forces analysis 2023

Exhibit 12: Bargaining power of buyers

Exhibit 13: Bargaining power of suppliers

Exhibit 14: Threat of new entrants

Exhibit 15: Threat of substitutes

Exhibit 16: Threat of rivalry

Exhibit 17: Market condition – Five forces 2018

Exhibit 18: Product – Market share 2018-2023 (%)

Exhibit 19: Comparison by product

Exhibit 20: Combination therapy – Market size and forecast 2018-2023 ($ millions)

Exhibit 21: Combination therapy – Year-over-year growth 2019-2023 (%)

Exhibit 22: Monotherapy – Market size and forecast 2018-2023 ($ millions)

Exhibit 23: Monotherapy – Year-over-year growth 2019-2023 (%)

Exhibit 24: Market opportunity by product

Exhibit 25: Customer landscape

Exhibit 26: Market share by geography 2018-2023 (%)

Exhibit 27: Geographic comparison

Exhibit 28: North America – Market size and forecast 2018-2023 ($ millions)

Exhibit 29: North America – Year-over-year growth 2019-2023 (%)

Exhibit 30: Top 3 countries in North America

Exhibit 31: Europe – Market size and forecast 2018-2023 ($ millions)

Exhibit 32: Europe – Year-over-year growth 2019-2023 (%)

Exhibit 33: Top 3 countries in Europe

Exhibit 34: Asia – Market size and forecast 2018-2023 ($ millions)

Exhibit 35: Proportion of geriatric population in Asia 2007 and 2017

Exhibit 36: Asia – Year-over-year growth 2019-2023 (%)

Exhibit 37: Top 3 countries in Asia

Exhibit 38: ROW – Market size and forecast 2018-2023 ($ millions)

Exhibit 39: ROW – Year-over-year growth 2019-2023 (%)

Exhibit 40: Top 3 countries in ROW

Exhibit 41: Key leading countries

Exhibit 42: Market opportunity

Exhibit 43: Pipeline molecules

Exhibit 44: Growth in geriatric population 2013-2017 (%)

Exhibit 45: Side effects of drugs treating mantle cell lymphoma

Exhibit 46: Impact of drivers and challenges

Exhibit 47: Drug designations

Exhibit 48: Recently approved drug designations to drug candidates aimed to treat mantle cell lymphoma

Exhibit 49: Vendor landscape

Exhibit 50: Landscape disruption

Exhibit 51: Vendors covered

Exhibit 52: Vendor classification

Exhibit 53: Market positioning of vendors

Exhibit 54: Allergan Plc – Vendor overview

Exhibit 55: Allergan Plc – Business segments

Exhibit 56: Allergan Plc – Organizational developments

Exhibit 57: Allergan Plc – Geographic focus

Exhibit 58: Allergan Plc – Segment focus

Exhibit 59: Allergan Plc – Key offerings

Exhibit 60: Allergan Plc – Key customers

Exhibit 61: AstraZeneca Plc – Vendor overview

Exhibit 62: AstraZeneca Plc – Product segments

Exhibit 63: AstraZeneca Plc – Organizational developments

Exhibit 64: AstraZeneca Plc – Geographic focus

Exhibit 65: AstraZeneca Plc – Key offerings

Exhibit 66: AstraZeneca Plc – Key customers

Exhibit 67: Celgene Corp. – Vendor overview

Exhibit 68: Celgene Corp. – Business segments

Exhibit 69: Celgene Corp. – Organizational developments

Exhibit 70: Celgene Corp. – Geographic focus

Exhibit 71: Celgene Corp. – Key offerings

Exhibit 72: Celgene Corp. – Key customers

Exhibit 73: Johnson & Johnson Services, Inc. – Vendor overview

Exhibit 74: Johnson & Johnson Services, Inc. – Business segments

Exhibit 75: Johnson & Johnson Services, Inc. – Organizational developments

Exhibit 76: Johnson & Johnson Services, Inc. – Geographic focus

Exhibit 77: Johnson & Johnson Services, Inc. – Segment focus

Exhibit 78: Johnson & Johnson Services, Inc. – Key offerings

Exhibit 79: Johnson & Johnson Services, Inc. – Key customers

Exhibit 80: Takeda Pharmaceutical Co. Ltd. – Vendor overview

Exhibit 81: Takeda Pharmaceutical Co. Ltd. – Business segments

Exhibit 82: Takeda Pharmaceutical Co. Ltd. – Organizational developments

Exhibit 83: Takeda Pharmaceutical Co. Ltd. – Geographic focus

Exhibit 84: Takeda Pharmaceutical Co. Ltd. – Key offerings

Exhibit 85: Takeda Pharmaceutical Co. Ltd. – Key customers

Exhibit 86: Validation techniques employed for market sizing

Exhibit 87: Definition of market positioning of vendors



【掲載企業】

Allergan Plc, AstraZeneca Plc, Celgene Corp., Johnson & Johnson Services Inc., and Takeda Pharmaceutical Co. Ltd.

【免責事項】
※当資料上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当資料に記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当資料上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチはその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチが翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

[マントル細胞リンパ腫治療法の世界市場:併用療法、単独療法]についてメールでお問い合わせはこちら


◆H&Iグローバルリサーチ株式会社のお客様(例)◆